| Pharmaceutical Information |
| Drug Name |
Idarucizumab |
| Drug ID |
BADD_D01129 |
| Description |
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin use, etc).
Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations. Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of dabigatran.
Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199. |
| Indications and Usage |
For use in patients treated with Dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding. |
| Marketing Status |
Prescription |
| ATC Code |
V03AB37 |
| DrugBank ID |
DB09264
|
| KEGG ID |
D10741
|
| MeSH ID |
C000594745
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0B9FW
|
| NDC Product Code |
0597-0197 |
| Synonyms |
idarucizumab | Praxbind | BI-655075 | BI655075 | BI 655075 | ADABI-FAB |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
1362509-93-0 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
